EcoDrugPlus

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSLCRG00005003185
Gene Symbol: GABBR1
3 Cross references
190 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSLCRG00005015709
Gene Symbol: GABBR1
3 Cross references
197 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSLCRG00005008181
Gene Symbol: GLP2R
3 Cross references
204 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSLCRG00005008228
Gene Symbol: GCGR
3 Cross references
164 Possible Orthologues:

Glucokinase (Hexokinase 4)

Ensembl ID : ENSLCRG00005011103
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSLCRG00005008261
Gene Symbol: GBA1
3 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSLCRG00005005278
Gene Symbol: GRIN1
3 Cross references
150 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSLCRG00005011896
Gene Symbol: GRIN2A
3 Cross references
228 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSLCRG00005000832
Gene Symbol: GRIN2B
3 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSLCRG00005000627
Gene Symbol: GRIN2C
3 Cross references
115 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSLCRG00005021644
Gene Symbol: GRIN2C
3 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSLCRG00005023636
Gene Symbol: GRIN3A
3 Cross references
245 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).